Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo).

被引：0

作者：

Ali, Sana

Leong, Sally

Meza, Luis A.

Dizman, Nazli

Zengin, Zeynep Busra

Kim, Tane

Pak, Youngju

Onyshchenko, Mykola

Pal, Sumanta K.

Chehrazi-Raffle, Alex

机构：

[1] Harbor UCLA Med Ctr, Torrance, CA USA

[2] City Hope Comprehens Canc Ctr, Duarte, CA USA

[3] Lundquist Res Inst, Torrance, CA USA

[4] UCLA David Geffen Sch Med, Harbor UCLA Med Ctr, Los Angeles, CA USA

[5] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Duarte, CA USA

[6] City Hope Natl Med Ctr, Duarte, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4554

引用

页数：1